Rallybio
RLYB
49 hedge funds and large institutions have $36.5M invested in Rallybio in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 18 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.14% less ownership
Funds ownership: 9.54% → 9.4% (-0.14%)
14% less capital invested
Capital invested by funds: $42.4M → $36.5M (-$5.87M)
26% less funds holding
Funds holding: 66 → 49 (-17)
50% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 22
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Almitas Capital
Santa Monica,
California
|
+$933K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$81.4K |
| 3 |
Two Sigma Advisers
New York
|
+$80.8K |
| 4 |
Renaissance Technologies
New York
|
+$75.9K |
| 5 |
Two Sigma Investments
New York
|
+$39.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$375K |
| 2 |
Goldman Sachs
New York
|
-$243K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$202K |
| 4 |
CPX
Canaan Partners XI
Menlo Park,
California
|
-$179K |
| 5 |
Millennium Management
New York
|
-$141K |
RLYB Hedge Fund Activity: Q3 2024 in Review
49 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Rallybio (RLYB) for Q3 2024, worth a combined $36.5M — down 14% from $42.4M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of RLYB and 1 opened new positions — a net loss of 17 holders — while 22 trimmed existing stakes and 11 added.
The largest buyer was Almitas Capital, adding an estimated $933K. The largest seller was Citadel Advisors, exiting entirely with an estimated $375K sold.
- 49 institutional investors held Rallybio (RLYB) as of Q3 2024, down from 66 in Q2 2024.
- Funds reported $36.5M of Rallybio stock for Q3 2024, down 14% quarter-over-quarter.
- 1 fund opened new Rallybio positions in Q3 2024 and 18 closed out, a net change of -17 holders.
- The largest Rallybio buyer in Q3 2024 was Almitas Capital, an estimated $933K added.
- The largest Rallybio seller in Q3 2024 was Citadel Advisors, an estimated $375K sold.
Based on aggregated 13F filings for Q3 2024.